3 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 25 points (-0.2%) at 14,513 as of Friday, March 15, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,309 issues advancing vs. 1,578 declining with 140 unchanged.

The Health Care sector currently sits down 0.1% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Intuitive Surgical ( ISRG), down 4.8%, Edwards Life ( EW), down 2.8%, Stryker Corporation ( SYK), down 1.0%, Baxter International ( BAX), down 1.1% and Amgen ( AMGN), down 0.8%.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector lower today:

3. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Health Care sector lower today. As of noon trading, Teva Pharmaceutical Industries is down $0.27 (-0.7%) to $40.79 on light volume Thus far, 1.6 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.9 million shares. The stock has ranged in price between $40.78-$41.16 after having opened the day at $41.10 as compared to the previous trading day's close of $41.06.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $34.9 billion and is part of the drugs industry. The company has a P/E ratio of 18.1, above the S&P 500 P/E ratio of 17.7. Shares are up 10.0% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 15 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Teva Pharmaceutical Industries Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Gilead ( GILD) is down $0.64 (-1.4%) to $45.24 on heavy volume Thus far, 7.3 million shares of Gilead exchanged hands as compared to its average daily volume of 9.1 million shares. The stock has ranged in price between $44.96-$46.00 after having opened the day at $45.81 as compared to the previous trading day's close of $45.88.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $69.8 billion and is part of the drugs industry. The company has a P/E ratio of 28.0, above the S&P 500 P/E ratio of 17.7. Shares are up 24.9% year to date as of the close of trading on Thursday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gilead Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Celgene Corporation ( CELG) is down $1.39 (-1.2%) to $112.89 on average volume Thus far, 2.6 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $112.71-$114.29 after having opened the day at $114.24 as compared to the previous trading day's close of $114.28.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $47.3 billion and is part of the drugs industry. The company has a P/E ratio of 34.3, above the S&P 500 P/E ratio of 17.7. Shares are up 45.6% year to date as of the close of trading on Thursday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%